Key result
Falipamil cuts atropine-induced heart rate increases by ~87% vs placebo while prolonging QT.
Why the study?
The pharmacological effects and safety profiles of two specific bradycardic agents, falipamil and ULFS 49 Cl, required evaluation under controlled conditions.
RCT
Double-blind
randomized
No takes yet. Share an insight, caveat, or question.
Confirms bradycardic effects of falipamil and ULFS 49 Cl in volunteers; leaves open translation to patient tachycardia or ischemia.
Su et al. (1987) reported an RCT. Falipamil and ULFS 49 Cl vs. Placebo was evaluated on Heart rate. Falipamil blunted atropine-induced heart rate increases (3% vs 23% with placebo) and increased QT-interval by 20%, while ULFS 49 Cl reduced heart rate without changing QT-time or blood pressure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: